Company Overview and News
Tlou Energy Ltd (LON:TLOU) managing director Tony Gilby and general manager Solomon Rowland chat to Proactive's Andrew Scott following an update on operations at the Lesedi coalbed methane project.
Tlou Energy Ltd (LON:TLOU) told investors that the closing date has been extended for proposals in the process for the coal-bed-methane fuelled power project in Botswana.
Tlou Energy Ltd (LON:TLOU), in its quarterly update, reminded investors that it is working to secure a clear pathway towards a gas-to-power pilot project in Botswana.
Tlou Energy Ltd (LON:TLOU) told investors on Wednesday that its core drilling rig has arrived on site of the Lesedi coal bed methane (CBM) project in Botswana.
Tlou Energy Limited (LON:TLOU ASX:TOU) said it is currently planning a drilling programme for production wells at its Lesedi coal bed methane (CBM) project to start in the third quarter of this year.
Tlou Energy Ltd (LON:TLOU) updated investors on its activities in the three months ended March 31, in which the company focussed on the Lesedi and Mamba coal bed methane (CBM) projects in Botswana.
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to ASX:TOU / TLOU ENERGY LIMITED on message board site Silicon Investor.